Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2471 to 2480 of 2683 total matches.
Budesonide (Entocort EC) For Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002 (Issue 1122)
. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 years, $132.00 ($27.50—U.S. Funds—per year for individual ...
Budesonide (Entocort EC AstraZeneca), a locally active glucocorticosteriod widely used for inhalation treatment of allergic rhinitis and asthma (Medical Letter 2000; 42:19), has been approved for oral treatment of mild to moderate active Crohn's disease involving the ileum and/or ascending colon. Both oral budesonide and budesonide enemas have been available for years in Europe and Canada for treatment of inflammatory bowel disease.
Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
The Medical Letter on Drugs and Therapeutics • Nov 25, 2002 (Issue 1144)
et al, Curr Pharm Biotechnol 2000; 1:303).
PHARMACOLOGY — The effective plasma half-life of Y-90 ...
Yttrium-90 ibritumomab tiuxetan (Zevalin -IDEC) was approved by the FDA for treatment of patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with follicular lymphoma refractory to rituximab (Rituxan -Medical Letter 1998; 40:65). Zevalin is the first radioimmunoconjugate to be approved for treatment of cancer.
Iodine-131 Tositumomab (Bexxar) for Treatment of Lymphoma
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
et al, Blood 2002; 100 (11 part 1):375a, abstract 1385; AD
Zelenetz, Semin Oncol 2003; 30 suppl 4:22 ...
Bexxar, a combination of the monoclonal antibody tositumomab and radiolabeled Iodine-131 tositumomab (Corixa Corp/GlaxoSmithKline) has been approved by the FDA for a single treatment of relapsed follicular non-Hodgkin's lymphoma (NHL) in patients who are refractory to rituximab (Rituxan - Medical Letter 1998; 40:65). It is the second radioimmunoconjugate to be approved for refractory NHL; yttrium-90 linked to ibritumomab tiuxetan (Zevalin) was approved in 2002. Tositumomab, like ibritumomab, is a monoclonal antibody of mouse origin that binds to the CD20 antigen present on the surface of >90%...
In Brief: Dexrazoxane for Anthracycline Extravasation
The Medical Letter on Drugs and Therapeutics • Dec 03, 2007 (Issue 1275)
) as an IV infusion over 1-2 hours as soon
as possible (no later than 6 hours) after extravasation ...
The FDA has approved a new formulation of dexrazoxane (Totect) for treatment of extravasation from intravenous (IV) anthracyclines such as doxorubicin (Adriamycin, and others). Dexrazoxane has been available since 1995 as Zinecard for protection against the cardiac toxicity of anthracyclines (Med Lett Drugs Ther 1995; 37:110). It is also available generically. The drug’s precise mechanism of action is not known, but anthracyclines are vesicants that bind to DNA and act as oxidizing agents in the presence of iron. Dexrazoxane is a topoisomerase inhibitor, possibly interfering with...
Resveratrol
The Medical Letter on Drugs and Therapeutics • Sep 21, 2009 (Issue 1321)
in regulation of molecular mechanisms of
aging.
1
Caloric restriction also increases sirtuin activity ...
Resveratrol is a phytochemical found in the skin of red grapes and in many other plants, including berries, plums and peanuts. As a constituent of red wine, it has been associated with cardioprotective effects. Dietary supplements containing resveratrol are now being widely promoted as antioxidants that can prevent agerelated diseases.
Pralatrexate (Folotyn) for Peripheral T-Cell Lymphoma
The Medical Letter on Drugs and Therapeutics • Jul 12, 2010 (Issue 1342)
of nonHodgkin’s lymphoma (NHL) in North America.
1
The
most common subtypes are PTCL not otherwise specified ...
The FDA has approved pralatrexate (Folotyn – Allos), an intravenous (IV) antifolate, for treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is the first drug approved by the FDA specifically for this indication.
A New Low-Dose Levonorgestrel-Releasing IUD (Skyla)
The Medical Letter on Drugs and Therapeutics • Mar 18, 2013 (Issue 1412)
gradually over 5 years to 10 mcg/day.1
MECHANISM OF ACTION — Local progestogenic
effects that interfere ...
The FDA recently approved Skyla (Bayer), the first new
intrauterine device (IUD) in the US in 12 years. It
releases levonorgestrel, a synthetic progestin, over a
period of 3 years. A table summarizing contraceptive
methods available in the US appears on page 22.
Comparison Chart: Correct Use of Inhalers for Asthma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
, the inhaler is ready to use
▶ The dose indicator should count down by 1
▶ Exhale fully
▶ Close lips around ...
View the Comparison Chart: Correct Use of Inhalers for Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e196-8 doi:10.58347/tml.2024.1716c | Show Introduction Hide Introduction
Tinidazole (Tindamax) - A New Anti-Protozoal Drug
The Medical Letter on Drugs and Therapeutics • Aug 30, 2004 (Issue 1190)
metronidazole 1.6 g divided into 2 doses to tinidazole 2 g once showed
no differences in cure rates or adverse ...
Tinidazole (Tindamax - Presutti Labs), an oral antiprotozoal drug similar to metronidazole (Flagyl, and others), has been approved by the FDA for treatment of trichomoniasis in adults and for treatment of giardiasis, intestinal amebiasis and amebic liver abcess in adults and children more than 3 years old. Tinidazole has been widely used outside of the US for decades under the trade name Fasigyn (Pfizer).
Two New Drugs for Renal Cell Carcinoma
The Medical Letter on Drugs and Therapeutics • Feb 26, 2007 (Issue 1255)
syndrome), but with a median duration of 54 months.
1
SUNITINIB — Mechanism of Action – Sunitinib ...
Sunitinib (Sutent - Pfizer) and sorafenib (Nexavar - Bayer), two oral tyrosine kinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma (RCC). Sunitinib is also approved for use in patients with gastrointestinal stromal tumor (GIST) who are not responding to or are intolerant of standard therapy with imatinib (Gleevec).
